Health Care

4432 posts
Rejection concept

Mayne Pharma plummets -30% as foreign review board rejects Cosette buyout

Mayne Pharma has revealed a letter from Chalmers has outlined that the gov't (via the FIRB)…
Blood plasma in a bag

CSL tumbles -15% as it points to reduced vaccination rates in US; lower Chinese demand

CSL Limited has tumbled nearly -15% in Tuesday trades after the market balked at its latest…
Lung imaging concept

4DMedical climbing back towards $2/sh on back of Stanford lung imaging tech rollout

4DX Medical has popped once again on Wednesday after demonstrating its next-generation lung imaging tech at…
Pearl shell double yolk AI gen

Orthocell coughs up $1M for 12% stake in WA biotech using pearl shells to create bone healing matrix

Orthocell Ltd has boosted its stake in a Western Australia-based biotech company called 'PearlBone,' which uses…
Excessive sweat

Botanix jumps back above 15cps on ‘65%’ revenue growth to $7M; new sales force boost

Botanix latest quarterly earnings report showed that revenues from anti-sweating drug Sofdra have increased to $7.1…

Compumedics wraps up $2.15M raise to accelerate Somfit D commercialisation

Compumedics has completed a $2.15 million placement to accelerate the commercialisation of its Somfit D sleep…
Magic mushrooms

ASX-listed Tryptamine Therapeutics launches binge eating trial using IV ‘magic mushroom’ drug

In a matter of weeks, Tryptamine Therapeutics (ASX:TYP) will become the world’s first company to conduct a study using
US cash concept

Painchek inks $40K contract with first US customer for aged care app days after FDA approval – but market’s wanting more

Painchek dipped red Monday following the company's news it's inked a deal with a Jewish Home…

Compumedics sees record sales orders, continued momentum across core and emerging platforms

Compumedics (ASX:CMP) has seen record sales orders and continued momentum across its core and emerging platforms.
Topical gel concept

Recce Pharma has a silver bullet for antibiotic-resistant superbugs. Phase III trials are now underway

Recce Pharmaceuticals (ASX:RCE) has been progressing its way – or that for its flagship breakthrough anti-infective drug, R327 – through